{"nctId":"NCT00133705","briefTitle":"Trial of Mifepristone for Fibroids","startDateStruct":{"date":"2003-07"},"conditions":["Leiomyoma"],"count":70,"armGroups":[{"label":"Mifepristone","type":"EXPERIMENTAL","interventionNames":["Drug: Mifepristone"]},{"label":"Inert capsule","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Inert Capsule"]}],"interventions":[{"name":"Mifepristone","otherNames":["RU486"]},{"name":"Inert Capsule","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Gender: Female\n* Age: 18 - premenopausal\n* Have at least moderate symptoms of menorrhagia or pelvic pain/pressure\n* Have a total uterine volume greater than or equal to 160 cc by ultrasound measurement and at least one fibroid that is =\\> 2.5cm in size\n* Have a score of equal to or greater than 39 on the Uterine Fibroid Symptom and Quality of Life scale\n* Declined standard treatment options for symptomatic fibroids\n* Agree to use a double-barrier method (condoms, diaphragms) or other effective non-hormonal methods of contraception (abstinence, sterilization) throughout participation in the study to prevent pregnancy and to report any exposure to pregnancy to the research staff immediately\n* Willing and able to give informed consent\n* Willing and able to comply with study requirements\n\nExclusion Criteria:\n\n* Current or planned pregnancy during the study period\n* Menopausal, as indicated by follicle stimulating hormone (FSH) level of the reference laboratory\n* Currently breast-feeding\n* Untreated abnormal pap smear\n* Presence of conditions other than fibroids contributing to pain and/or bleeding\n* Hemoglobin \\< 9.0 mg/dl\n* Presence of adnexal masses or tenderness indicating further evaluation or surgery\n* Grade III or IV hydronephrosis by ultrasound\n* Severe, active mental health disorder\n* Active substance abuse or dependence\n* Presence of any contraindication to mifepristone including:\n\n  * Adrenal insufficiency by history\n  * Sickle cell disease\n  * Active liver disease (liver function tests greater than 1.5 times upper range of normal)\n  * Severe, respiratory disease (P02 saturation\\< 92%)\n  * Renal disease (serum creatinine \\> 1.5 mg/dl)\n  * Blood clotting defect. (abnormal PT and PTT)\n  * Thromboembolic disease (history of deep vein thrombosis or pulmonary embolus)\n* Current or recent (within the past 3 months) use of the following medications:\n\n  * Oral or systemic corticosteroids\n  * Hormones: estrogens, progestins, oral contraceptives\n  * Danazol, anticoagulants\n* Herbal or botanical supplements with possible hormonal effects.\n* Use within the past six months of the gonadotropin releasing hormones (GnRH) analogs or Depo-Provera.\n* Current or planned use during the study of any of the following medications/or products:\n\n  * ketoconazole,\n  * itraconazole,\n  * erythromycin,\n  * grapefruit juice,\n  * rifampin,\n  * St John's Wort,\n  * phenytoin,\n  * phenobarbital, or\n  * carbamazepine","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Uterine Volume","description":"Uterine volume is measured in mLs","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"719","spread":"663"},{"groupId":"OG001","value":"449","spread":"236"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":22},"commonTop":[]}}}